SCHEMBL7712797

SCHEMBL7712797

CC1Oc2ccc(CN(Cc3cccc(F)c3)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.36
PARP1 P09874 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
TSPO P30536 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704932 0.92 HDAC3 (0.35) RIPK1PARP1HDAC3HDAC1HDAC2
SCHEMBL6309617 0.91 HDAC1 (0.43) PARP1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7704945 0.91 HDAC3 (0.44) PARP1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7713256 0.90 PARP1 (0.48) RIPK1PARP1HDAC3HDAC1HDAC2
SCHEMBL7713431 0.89 PARP1 (0.35) PARP1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7708255 0.89 RIPK1 (0.36) RIPK1PARP1HDAC3HDAC1HDAC2
SCHEMBL7704942 0.88 ALDH1A1 (0.37) RIPK1PARP1HDAC3HDAC1HDAC2
SCHEMBL7711073 0.88 MEN1 (0.37) PARP1HDAC3HDAC1HDAC2NCOR2
SCHEMBL6428132 0.88 RIPK1 (0.36) RIPK1PARP1HDAC3HDAC1HDAC2
SCHEMBL6302929 0.88 PARP1 (0.35) PARP1HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed